News
Novartis receives approval for first malaria medicine for newborn babies and young infants
Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global health scheme run by Swiss agency for therapeutic products (Swissmedic)
Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.
Novartis has inked a deal with Sironax that gives the pharma the exclusive option to acquire the biotech’s blood-brain ...
A Delaware federal judge has ruled that Novartis cannot prevent MSN Pharmaceuticals from introducing a generic version of its ...
Novartis said on Thursday that its Cosentyx drug had failed in a late-stage trial on adults with giant cell arteritis (GCA), ...
As treatment for spinal muscular atrophy (SMA) has drastically improved over the last decade, so too have survival rates and the number of people with SMA living well into adulthood. | A new education ...
Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce the successful conclusion of negotiations with the pan ...
Investor's Business Daily on MSN3d
Stocks Generating Improved Relative Strength: Novartis ADRNovartis ADRNVS saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an increase from 69 to 76. Please watch the video at Investors.com - How To Scale Out Of Losing Stocks ...
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback